Shifting paradigms in multiple sclerosis: From disease-specific, through population-specific toward patient-specific

Current Opinion in Neurology

Volumn 29, Issue 3, 2016, Pages 354-361

  Golan, Daniel ^a,b   Staun Ram, Elsebeth ^b   Miller, Ariel ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

biomarkers; digital sensor; multiple sclerosis; personalized medicine; population epigenetics; quality of life

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; NATALIZUMAB; IMMUNOLOGIC FACTOR;

EMPOWERMENT; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC ANALYSIS; HUMAN; MULTIPLE SCLEROSIS; PHARMACOGENETICS; PROGNOSIS; REVIEW; TREATMENT RESPONSE; DISEASE MANAGEMENT; PERSONALIZED MEDICINE;

DISEASE MANAGEMENT; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PRECISION MEDICINE;

EID: 84963665049     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000324     Document Type: Review

References (85)

1. Heidenreich F. Long-term treatment of relapsing-remitting multiple sclerosis with interferon b: how strongly should we encourage patients to adhere to the 'old' therapies? J Neurol Neurosurg Psychiatry 2015; 86:1171.
2. von Büdingen H-C, Palanichamy A, Lehmann-Horn K, et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol 2015; 73:238-246.
3. Shirani A, Okuda DT, Stüve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics 2016; 13:58-69.
4. Barizzone N, Zara I, Sorosina M, et al. The burden of multiple sclerosis variants in continental Italians and Sardinians. Mult Scler 2015; 21:1385-1395.
5. Pandit L, Malli C, Singhal B, et al. HLA associations in South Asian multiple sclerosis. Mult Scler 2016; 22:19-24.
6. Moutsianas L, Jostins L, Beecham AH, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet 2015; 47:1107-1113.
7. Alter M, Kahana E, Zilber N, Miller A. Multiple sclerosis frequency in Israel' s diverse populations. Neurology 2006; 66:1061-1066.
8. Khankhanian P, Matsushita T, Madireddy L, et al. Genetic contribution to multiple sclerosis risk among Ashkenazi Jews. BMC Med Genet 2015; 16:55-65.
9. Siegel M, Paperna T, Lejbkowicz I, et al. Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in Israel. Mult Scler 2012; 18:1737-1744.
10. Benedek G, Paperna T, Avidan N, et al. Opposing effects of the HLA-DRB1∗0301-DQB1∗0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel. Genes Immun 2010; 11:423-431.
11. Grossman I, Avidan N, Singer C, et al. Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity. Genes Immun 2004; 5:493-504.
12. Paradas C, Akman HO, Ionete C, et al. Branching enzyme deficiency: expanding the clinical spectrum. JAMA Neurol 2014; 71:41-47.
13. Hellmann MA, Kakhlon O, Landau EH, et al. Frequent misdiagnosis of adult polyglucosan body disease. J Neurol 2015; 262:2346-2351.
14. Shohat M, Halpern GJ. Familial Mediterranean fever: a review. Genet Med 2011; 13:487-498.
15. Yahalom G, Kivity S, Lidar M, et al. Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world's largest FMF cohorts. Eur J Neurol 2011; 18:1146-1150.
16. Shinar Y, Livneh A, Villa Y, et al. Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashke-nazi Jewish multiple sclerosis patients. Genes Immun 2003; 4:197-203.
17. Simpson S, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:1132-1141.
18. Kinoshita M, Obata K, Tanaka M. Latitude has more significant impact on prevalence of multiple sclerosis than ultraviolet level or sunshine duration in Japanese population. Neurol Sci 2015; 36:1147-1151.
19. Sajedi SA, Abdollahi F. Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries. BMC Neurol 2012; 12:100-117.
20. Guimond C, Lee JD, Ramagopalan SV, et al. Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. Mult Scler 2014; 20:1182-1188.
21. Berg-Hansen P, Moen SM, Sandvik L, et al. Prevalence of multiple sclerosis among immigrants in Norway. Mult Scler 2015; 21:695-702.
22. Kingwell E, Zhu F, Marrie RA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). J Neurol 2015; 262:2352-2363.
23. Sellner J, Kraus J, Awad A, et al. The increasing incidence and prevalence of female multiple sclerosis: a critical analysis of potential environmental factors. Autoimmun Rev 2011; 10:495-502.
24. Mackenzie IS, Morant SV, Bloomfield GA, et al. Changing face of multiple sclerosis in the United Kingdom 1990-2010. An incidence and prevalence study. J Neurol Neurosurg Psychiatry 2013; 84:e2.
25. Solaro C, Ponzio M, Moran E, et al. The changing face of multiple sclerosis: prevalence and incidence in an aging population. Mult Scler J 2015; 21:1244-1250.
26. Espinosa-Raḿirez G, Ordonez G, Flores-Rivera J, Sotelo J. Sunlight exposure and multiple sclerosis in a tropical country. Neurol Res 2014; 36:647-650.
27. Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med 2015; 12:e1001866.
28. Picascia A, Grimaldi V, Pignalosa O, et al. Epigenetic control of autoimmune diseases: from bench to bedside. Clin Immunol 2015; 157:1-15.
29. Shah S, Bonder MJ, Marioni RE, et al. Improving phenotypic prediction by combining genetic and epigenetic associations. Am J Hum Genet 2015; 97:75-85.
30. Kroksveen AC, Opsahl JA, Guldbrandsen A, et al. Cerebrospinal fluid pro-teomics in multiple sclerosis. Biochim Biophys Acta 2015; 1854:746-756.
31. Menoret A, Crocker SJ, Rodriguez A, et al. Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform. Proteomics Clin Appl 2016; 10:8-24.
32. Housley WJ, Pitt D, Hafler DA. Biomarkers in multiple sclerosis. Clin Immunol 2015; 161:51-58.
33. Raphael I, Webb J, Stuve O, et al. Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol 2015; 11:69-91.
34. D'Ambrosio A, Pontecorvo S, Colasanti T, et al. Peripheral blood biomarkers in multiple sclerosis. Autoimmun Rev 2015; 14:1097-1110.
35. Trentini A, Comabella M, Tintore M, et al. N-acetyl aspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014; 261:2338-2343.
36. Giovannoni G, Nath A. After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage. Neurology 2011; 76:1200-1201.
37. Khalil M, Enzinger C, Langkammer C, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19:436-442.
38. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neuro-surg Psychiatry 2016; 87:126-129.
39. Martinez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cere-brospinal fluid predict progression in multiple sclerosis. Mult Scler J 2015; 21:550-561.
40. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009; 72:1322-1329.
41. Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 2011; 258:882-888.
42. Hinsinger G, Galéotti N, Nabholz N, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 2015; 21:1251-1261.
43. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133:1082-1093.
44. Cantó E, Tintoré M, Villar LM, Costa C, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015; 138:918-931.
45. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011; 17:335-343.
46. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010; 5:e11986.
47. Stilund M, Gjelstrup MC, Petersen T, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One 2015; 10:e0119681.
48. Ferraro D, Galli V, Vitetta F, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. J Neuroimmunol 2015; 283:64-69.
49. Graber JJ, Dhib-Jalbut S. Biomarkers of interferon beta therapy in multiple sclerosis. J Interferon Cytokine Res 2014; 34:600-604.
50. Bertolotto A, Granieri L, Marnetto F, et al. Biological monitoring of IFN-b therapy in multiple sclerosis. Cytokine Growth Factor Rev 2015; 26:241-248.
51. Link J, Lundkvist Ryner M, Fink K, et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing antidrug antibodies in multiple sclerosis. PLoS One 2014; 9:e90479.
52. Núñez C, Cénit MC, Alvarez-lafuente R, et al. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-b therapy in multiple sclerosis. J Med Genet 2014; 51:395-400.
53. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69:83-89.
54. Harris VK, Donelan N, Yan QJ, et al. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult Scler 2013; 19:1462-1472.
55. Romme Christensen J, Ratzer R, Börnsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82:1499-1507.
56. Iaffaldano P, Ruggieri M, Viterbo RG, et al. The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in natalizumab treated relapsing multiple sclerosis. Brain Behav Immun 2014; 35:96-101.
57. Malmeström C, Axelsson M, Lycke J, et al. CSF levels ofYKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol 2014; 269:87-89.
58. Stoop MP, Singh V, Stingl C, et al. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res 2013; 12:1101-1107.
59. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870-1880.
60. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016; 87:117-125.
61. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81:865-871.
62. Schwab N, Schneider-Hohendorf T, Pignolet B, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler J 2015; 96:1-13.
63. Lieberman L, Zeng W, Singh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology 2016; 86:375-381.
64. Basnyat P, Hagman S, Kolasa M, et al. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord 2015; 4:334-338.
65. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84:1639-1643.
66. Mahurkar S, Suppiah V, O'Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev 2014; 13:178-186.
67. Carlson RJ, Doucette JR, Knox K, Nazarali AJ. Pharmacogenomics of inter-feron-(beta) in multiple sclerosis: what has been accomplished and how can we ensure future progress? Cytokine Growth Factor Rev 2015; 26:249-261.
68. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65:337-344.
69. Comabella M, Craig DW, Morcillo-Suarez C, et al. Genome-wide scan of 500 000 single-nucleotide polymorphisms among responders and non-responders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66:972-978.
70. Esposito F, Sorosina M, Ottoboni L, et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol 2015; 78:115-127.
71. Clarelli F, Liberatore G, Sorosina M, et al. Pharmacogenetic study of long-term response to interferon-b treatment in multiple sclerosis. Pharmacogenomics J 2015; doi:10.1038/tpj.2015.85. [Epub ahead of print]
72. Bustamante MF, Morcillo-Suarez C, Malhotra S, et al. Pharmacogenomic study in patients with multiple sclerosis: responders and nonresponders to IFN-b. Neurol Neuroimmunol Neuroinflammation 2015; 2:e154-e1154.
73. Bustamante MF, Fissolo N, Rio J, et al. Implication of the Toll-like receptor 4 pathway in the response to interferon-beta in multiple sclerosis. Ann Neurol 2011; 70:634-645.
74. Malhotra S, Río J, Urcelay E, et al. NLRP3 inflammasome is associated with the response to IFN-b in patients with multiple sclerosis. Brain 2015; 138:644-652.
75. Ionescu R, Broza Y, Shaltieli H, et al. Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes. ACS Chem Neurosci 2011; 2:687-693.
76. Pieragostino D, D'Alessandro M, di Ioia M, et al. An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. Mol Biosyst 2015; 11:1563-1572.
77. Afonina IS, Beyaert R. Trabid epigenetically drives expression of IL-12 and IL-23. Nat Immunol 2016; 17:227-228.
78. Kotelnikova E, Bernardo-Faura M, Silberberg G, et al. Signaling networks in MS: a systems-based approach to developing new pharmacological therapies. Mult Scler J 2015; 21:138-146.
79. Lejbkowicz I, Caspi O, Miller A. Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Rev Neurother 2012; 12:343-352.
80. Brigo F, Lochner P, Tezzon F, Nardone R. Web search behavior for multiple sclerosis: an infodemiological study. Mult Scler RelatDisord 2014; 3:440-443.
81. Lejbkowicz I, Paperna T, Stein N, et al. Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcare. Mult Scler Int 2010; 2010:640749.
82. Synnot AJ, Hill SJ, Garner KA, et al. Online health information seeking: how people with multiple sclerosis find, assess and integrate treatment information to manage their health. Health Expectations 2014; doi:10.1111/hex.12253. [Epub ahead of print]
83. Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother 2014; 14:1029-1042.
84. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
85. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793-795.